Please login to the form below

Not currently logged in
Email:
Password:

Pliva finalises German oncology business acquisition

Pliva reveals that its German subsidiary AWD Pharma signed an agreement to acquire ORCA Pharm, a privately owned pharmaceutical company with a presence in the oncology market in that region

Croatia-headquartered Pliva has revealed that its German subsidiary AWD Pharma has signed an agreement to acquire ORCA Pharm, a privately owned pharmaceutical company with a presence in the oncology market in that region.

When the transaction is closed, AWD will pay a fixed purchase price of EUR 21m and up to an additional EUR 13m, based on the achievement of profitability milestones for 2007 and 2008.

Zeljko Covic, President and COO of Pliva, said: "Our acquisition of ORCA pharm provides us with a strategic platform for entering the highly lucrative oncology business in Germany and strongly supports our corporate strategy of focusing on markets with greater barriers-to-entry and thus greater value."

"The acquisition of ORCA pharm and its current product portfolio further supports our commitment to the EU oncology market and strengthens the foothold we have already established through our Czech subsidiary PLIVA Lachema, which focuses on the development, production and distribution of vertically integrated injectable cytostatic products," concluded Covic.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Healthcare in a lockdown
Even if patients are getting enough care during the COVID-19 pandemic, are they getting the right care?...
Love in the Time of Coronavirus
Having gone through 4 stages of coping with covid-19: first disbelief, then humour, then creative ways to deal with isolation, and finally the tragic realisation that lives are being lost...
The other side of … multiple sclerosis
No good comes from excluding patients from having a say in their own care. In fact, improving activation (& outcomes) demands it....

Infographics